Vraylar and Caplyta for Adjunct Therapy in Anhedonia
Vraylar (cariprazine) is FDA-approved and has demonstrated efficacy as adjunct therapy for major depressive disorder, with specific evidence showing improvement in anhedonia symptoms, while Caplyta (lumateperone) is FDA-approved for bipolar depression but lacks FDA approval or robust evidence for adjunctive use in treating anhedonia specifically.
FDA-Approved Indications
Vraylar (Cariprazine)
Vraylar is FDA-approved for adjunctive treatment of major depressive disorder (MDD) 1. The drug label demonstrates:
- Study 10: Cariprazine 1.5 mg/day + antidepressant showed statistically significant superiority over placebo + antidepressant (MADRS difference: -2.5,95% CI: -4.2 to -0.9) 1
- Study 11: Cariprazine 2-4.5 mg/day + antidepressant demonstrated significant benefit (MADRS difference: -2.2,95% CI: -3.7 to -0.6) 1
Caplyta (Lumateperone)
Caplyta is FDA-approved for bipolar depression as monotherapy or adjunctive therapy with lithium or valproate, but NOT for adjunctive treatment of MDD 2. The drug label shows efficacy only when combined with mood stabilizers in bipolar disorder, not with antidepressants in unipolar depression.
Evidence for Anhedonia Treatment
Vraylar's Anti-Anhedonic Effects
Cariprazine demonstrates specific anti-anhedonic properties beyond general antidepressant effects:
- In patients with MDD and moderate-to-severe anhedonia (MADRS anhedonia subscale ≥18), adjunctive cariprazine 1.5 mg/day showed significant improvement in both overall depression (LSMD: -3.4, p=0.0006) and anhedonia subscale scores (LSMD: -2.1, p=0.0010) 3
- The anti-anhedonic effect persisted after adjusting for other depressive symptoms, suggesting a specific rather than pseudospecific effect 4
- Cariprazine significantly improved the MADRS "inability to feel" item (item 8), a core measure of anhedonia 3
Caplyta's Limited Anhedonia Data
Caplyta showed improvement in anhedonia factor scores in bipolar depression (effect size: -0.47 in mixed population) 5, but this evidence is:
- Limited to bipolar disorder populations
- Not demonstrated in adjunctive therapy for MDD
- Not FDA-approved for this indication
Clinical Algorithm for Use
When to Use Vraylar as Adjunct Therapy:
- Patient has MDD with inadequate response to 1-3 antidepressant trials
- Prominent anhedonia symptoms are present (loss of interest, inability to feel pleasure, reduced motivation)
- Start with 1.5 mg/day - this dose showed the most consistent efficacy across studies 1, 3, 6
- The 3 mg/day dose is less reliably effective and should generally be avoided based on FDA data showing non-significant results in some trials 1
When NOT to Use Caplyta as Adjunct:
- Do not use Caplyta as adjunct therapy for MDD - it lacks FDA approval and supporting evidence for this indication
- Consider Caplyta only for bipolar depression, either as monotherapy or with lithium/valproate 2
Safety Considerations
Vraylar Tolerability in Adjunctive Use:
- High completion rates (90%) with mostly mild-to-moderate adverse events 7
- Common side effects (≥5% and twice placebo rate): akathisia, nausea, insomnia - with dose-dependent increases 7
- Metabolically neutral: mean weight gain <1 kg 7
- Discontinuation rate due to adverse events: 4.3% 7
Important Caveats:
- One negative trial (NCT01715805) showed no significant benefit of cariprazine adjunctive therapy 8, though this contrasts with two positive phase 3 trials
- Akathisia is the most common limiting side effect - monitor closely and consider dose reduction if it occurs
- The long half-life of cariprazine (1-3 weeks for active moieties) means effects and side effects persist after discontinuation
Bottom Line for Clinical Practice
For anhedonia in MDD with inadequate antidepressant response: Use Vraylar 1.5 mg/day as adjunct therapy. This is the only FDA-approved option with specific evidence for improving anhedonia symptoms in this population 1, 3, 6.
For anhedonia in bipolar depression: Consider Caplyta as monotherapy or with mood stabilizers, but recognize this is a different clinical scenario than adjunctive therapy for MDD 2, 5.
Do not use Caplyta as adjunct to antidepressants for MDD - this is off-label without supporting evidence and contradicts FDA-approved indications.